Associations of maternal per- and polyfluoroalkyl substance plasma concentrations during pregnancy with offspring polycystic ovary syndrome and related characteristics in project viva

被引:0
|
作者
Wang, Zifan [1 ]
Fleisch, Abby [2 ,3 ]
Rifas-Shiman, Sheryl L. [4 ,5 ]
Calafat, Antonia M. [6 ]
James-Todd, Tamarra [1 ,7 ]
Coull, Brent A. [1 ,8 ]
Chavarro, Jorge E. [9 ]
Hivert, Marie-France [4 ,5 ,10 ]
Whooten, Rachel C. [11 ]
Perng, Wei [12 ]
Oken, Emily [4 ,5 ,9 ]
Mahalingaiah, Shruthi [1 ,13 ]
机构
[1] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave,Bldg 1,Room 1404, Boston, MA 02115 USA
[2] MaineHealth Inst Res, Ctr Interdisciplinary Populat & Hlth Res, Westbrook, ME USA
[3] Maine Med Ctr, Pediat Endocrinol & Diabet, Portland, ME USA
[4] Harvard Med Sch, Dept Populat Med, Div Chron Dis Res Lifecourse, Boston, MA USA
[5] Harvard Pilgrim Hlth Care Inst, Boston, MA USA
[6] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Lab Sci, Atlanta, GA USA
[7] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[8] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA
[9] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA
[10] Massachusetts Gen Hosp, Diabet Unit, Boston, MA USA
[11] Massachusetts Gen Hosp Children, Dept Pediat, Boston, MA USA
[12] Univ Colorado Anschutz Med Campus, Dept Epidemiol & Lifecourse Epidemiol Adipos & Di, Aurora, CO USA
[13] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Boston, MA USA
基金
美国国家卫生研究院;
关键词
PFAS; Endocrine disrupting chemicals; Polycystic ovary syndrome; Menstrual cycle; Ovulatory dysfunction; Androgen excess; PERFLUOROALKYL SUBSTANCES; PRENATAL EXPOSURE; HORMONE-LEVELS; RISK; SERUM; AGE; CHEMICALS; PUBERTY; WOMEN; CYCLE;
D O I
10.1016/j.envres.2025.120786
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background: Per- and polyfluoroalkyl substances (PFAS) may impact ovarian folliculogenesis and steroidogenesis, but whether prenatal exposure may impact offspring reproductive health is unknown. This study examines the extent to which maternal PFAS plasma concentrations during pregnancy are associated with polycystic ovary syndrome (PCOS) and related characteristics in female offspring. Methods: We studied 322 mother-daughter pairs in Project Viva, a Boston-area longitudinal pre-birth cohort enrolled 1999-2002. We examined associations of maternal prenatal (median: 9.6 weeks gestation) plasma concentrations of six PFAS (log2 transformed) with PCOS and related characteristics among daughters during mid-to-late adolescence. We estimated the associations of single PFAS and PFAS as a mixture with each outcome, using logistic regression and quantile g-computation, respectively, adjusting for parity, and maternal sociodemographic and other lifestyle/health factors. Results: Among the 322 mother-daughter pairs, the majority of mothers identified as non-Hispanic White and had a college degree, and 13% of daughters had either self-reported PCOS or probable PCOS based on irregular menstrual cycles and clinical or biochemical markers of hyperandrogenism. Among all daughters, there were 27% with irregular menstrual cycles, 34% with hirsutism, and 6% with moderate-to-severe acne. When fully adjusted for confounders, per doubling of maternal 2-(N-ethyl-perfluorooctane sulfonamido) acetate (EtFOSAA) concentration was associated with higher odds of self-reported PCOS [OR (95% CI) = 2.66 (1.18, 5.99)], and per doubling of maternal perfluorononanoate (PFNA) concentration was associated with higher odds of moderate-tosevere acne [OR (95% CI) = 2.33 (1.09, 4.99)] in daughters with or without irregular menstrual cycles. We found no associations of the mixture of six PFAS with PCOS or related traits.
引用
收藏
页数:10
相关论文
共 14 条
  • [1] Plasma concentrations of per- and polyfluoroalkyl substances in pregnancy and breastfeeding duration in Project Viva
    Rokoff, Lisa B.
    Wallenborn, Jordyn T.
    Harris, Maria H.
    Rifas-Shiman, Sheryl L.
    Criswell, Rachel
    Romano, Megan E.
    Young, Jessica G.
    Calafat, Antonia M.
    Oken, Emily
    Sagiv, Sharon K.
    Fleisch, Abby F.
    SCIENCE OF THE TOTAL ENVIRONMENT, 2023, 891
  • [2] Pregnancy Per- and Polyfluoroalkyl Substance Concentrations and Postpartum Health in Project Viva: A Prospective Cohort
    Mitro, Susanna D.
    Sagiv, Sharon K.
    Fleisch, Abby F.
    Jaacks, Lindsay M.
    Williams, Paige L.
    Rifas-Shiman, Sheryl L.
    Calafat, Antonia M.
    Hivert, Marie-France
    Oken, Emily
    James-Todd, Tamarra M.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (09): : E3415 - E3426
  • [3] Maternal Plasma per- and Polyfluoroalkyl Substance Concentrations in Early Pregnancy and Maternal and Neonatal Thyroid Function in a Prospective Birth Cohort: Project Viva (USA)
    Preston, Emma V.
    Webster, Thomas F.
    Oken, Emily
    Henn, Birgit Claus
    McClean, Michael D.
    Rifas-Shiman, Sheryl L.
    Pearce, Elizabeth N.
    Braverman, Lewis E.
    Calafat, Antonia M.
    Ye, Xiaoyun
    Sagiv, Sharon K.
    ENVIRONMENTAL HEALTH PERSPECTIVES, 2018, 126 (02)
  • [4] Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohort
    Preston, Emma, V
    Hivert, Marie-France
    Fleisch, Abby F.
    Calafat, Antonia M.
    Sagiv, Sharon K.
    Perng, Wei
    Rifas-Shiman, Sheryl L.
    Chavarro, Jorge E.
    Oken, Emily
    Zota, Ami R.
    James-Todd, Tamarra
    ENVIRONMENT INTERNATIONAL, 2022, 165
  • [5] Associations of Per- and Polyfluoroalkyl Substances (PFAS) With Glucose Tolerance During Pregnancy in Project Viva
    Preston, Emma, V
    Rifas-Shiman, Sheryl L.
    Hivert, Marie-France
    Zota, Ami R.
    Sagiv, Sharon K.
    Calafat, Antonia M.
    Oken, Emily
    James-Todd, Tamarra
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (08): : E2864 - E2876
  • [6] Per- and Polyfluoroalkyl Substance Plasma Concentrations and Bone Mineral Density in Midchildhood: A Cross-Sectional Study (Project Viva, United States)
    Cluett, Rachel
    Seshasayee, Shravanthi M.
    Rokoff, Lisa B.
    Rifas-Shiman, Sheryl L.
    Ye, Xiaoyun
    Calafat, Antonia M.
    Gold, Diane R.
    Coull, Brent
    Gordon, Catherine M.
    Rosen, Clifford J.
    Oken, Emily
    Sagiv, Sharon K.
    Fleisch, Abby F.
    ENVIRONMENTAL HEALTH PERSPECTIVES, 2019, 127 (08)
  • [7] Per- and Polyfluoroalkyl Substances Serum Concentrations and Polycystic Ovary Syndrome among Women Attending a Fertility Clinic
    Zhang, Y.
    Martin, L.
    Mustieles, V.
    Ghaly, M.
    Archer, M.
    Yang, S.
    Torres, N.
    Coburn-Sanderson, A.
    Souter, I.
    Petrozza, J.
    Yixin, W.
    Messerlian, C.
    HUMAN REPRODUCTION, 2024, 39 : I470 - I470
  • [8] Maternal per- and polyfluoroalkyl substance concentrations and placental DNA methylation of thyroid hormone-related genes
    Xie, Zhenzhen
    Jin, Longmei
    Wu, Qihan
    Ji, Honglei
    Miao, Maohua
    Song, Xiuxia
    Zhu, Haijun
    Su, Huijia
    Yuan, Wei
    Liang, Hong
    JOURNAL OF HAZARDOUS MATERIALS, 2025, 489
  • [9] Prenatal Per- and Polyfluoroalkyl Substance (PFAS) Exposures and Offspring Blood Pressure From Birth to Late Adolescence: A Prospective Study in Project Viva
    Zhang, Mingyu
    Rifas-Shiman, Sheryl L.
    Aris, Izzuddin
    James-Todd, Tamarra
    Oken, Emily
    Hivert, Marie-France
    CIRCULATION, 2023, 147
  • [10] Plasma per- and polyfluoroalkyl substance mixtures during pregnancy and duration of breastfeeding in the New Hampshire birth cohort study
    Romano, Megan E.
    Gallagher, Lisa G.
    Price, George
    Crawford, Kathryn A.
    Criswell, Rachel
    Baker, Emily
    Botelho, Julianne Cook
    Calafat, Antonia M.
    Karagas, Margaret R.
    INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH, 2024, 258